Memory's Alzheimer's drug flunks Phase II

Memory Pharmaceuticals' MEM 1003 failed a Phase IIa study, falling short in demonstrating a statistically significant response for improved symptoms after 12 weeks of therapy among the 183 volunteers in the trial. The volunteers included patients on a monotherapy regimen and subjects on doses of cholinesterase inhibitors. Researchers said that an "unusually large" placebo response led to negative results for the monotherapy group and positive trends but no statistically significant data in the combination group.

- see the Memory release on the trial

Read more on: Alzheimer's

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.